

20 March 2025

**BIOPHARMA CREDIT PLC**

**(THE "COMPANY")**

**APPOINTMENT OF JOINT CORPORATE BROKER**

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to announce the appointment of Investec Bank plc as joint corporate broker to work alongside JPMorgan Cazenove, the Company's existing corporate broker, with effect from 10 March 2025.

The contact information for the Company's joint corporate brokers is as follows:

JPMorgan Cazenove	Investec Bank plc
William Simmonds william.simmonds@jpmorgancazenove.com	David Yovichic david.yovichic@investec.com
Mary-Jane Clarke mary-jane.clarke@jpmorgan.com	Lucy Lewis lucy.lewis@investec.com

**Enquiries:**

*BioPharma Credit plc*

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

*Burson Buchanan*

Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams

+44 (0)20 7466 5000

[biopharmacredit@buchanan.uk.com](mailto:biopharmacredit@buchanan.uk.com)

**Notes to Editors:**

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPGZGMFGLVGKZZ